Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Non-Randomized Phase 2 Study Evaluating SAR3419, an Anti-CD19 Antibody - Maytansine Conjugate, Administered as Single Agent by Intravenous Infusion to Patients With Relapsed or Refractory CD19+ Diffuse Large B-Cell Lymphoma

NCT01472887 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01472887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01472887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Non-Randomized Phase 2 Study Evaluating SAR3419, an Anti-CD19 Antibody - Maytansine Conjugate, Administered as Single Agent by Intravenous Infusion to Patients With Relapsed or Refractory CD19+ Diffuse Large B-Cell Lymphoma
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
September 30, 2016
Enrollment
61 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma